Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066528 · ClinicalTrials.gov registry record · Phase 3
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
A Phase 3 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 3
- Development phase
- 755
- Enrollment target
- 20
- Study locations
NCT06066528 is a Phase 3 study of Obesity and Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 755 participants, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT06066528, a Phase 3 study of Obesity and Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 755 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT Survodutide
Study Locations (20)
Florida
- Alliance for Multispecialty Research, LLC - Doral - Doral
- University of Florida - Gainesville
- East Coast Institute for Research, LLC - Jacksonville - Jacksonville
- New Horizon Research Center-Miami-69732 - Miami
- West Orange Endocrinology - Ocoee
California
- Encompass Clinical Research, Spring Valley - Spring Valley
- Diablo Clinical Research - Walnut Creek
Kentucky
- AMR Lexington - Lexington
- L-MARC Research Center - Louisville
New Jersey
- Walgreens Clinical Trials-Atlantic City-69647 - Atlantic City
- Walgreens - Perth Amboy - Site 4544 - Perth Amboy
Alabama
- Pinnacle Research Group, LLC - Anniston
Arizona
- EmVenio Research-Atlanta-69582 - Phoenix
Georgia
- Emory University - Atlanta
Hawaii
- East-West Medical Research - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 755 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2026-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06066528
The ClinicalTrials.gov registry entry for NCT06066528 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 755 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06066528 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06066528 about?
NCT06066528 is a clinical study titled "A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight". This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not ...
What is the current status of trial NCT06066528?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 755 participants. The study started on 2023-11-27. Estimated completion is 2026-04-03.
What conditions does trial NCT06066528 study?
This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT06066528?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Survodutide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06066528?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066528 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.